REBECCA MOONEY: Open Payments
NPI 1154323319 · ABERDEEN, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,174 in 186 payments from 23 companies in 2025. Trend: 2023 $2,632 · 2024 $3,649 · 2025 $4,174
Food & beverage: $4,074Education: $100
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 43 | $746 |
| Janssen Biotech, Inc. | 23 | $717 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 20 | $498 |
| Madrigal Pharmaceuticals | 18 | $399 |
| Takeda Pharmaceuticals U.S.A., Inc. | 14 | $355 |
| GENZYME CORPORATION | 11 | $302 |
| Ipsen Biopharmaceuticals, Inc | 6 | $179 |
| Phathom Pharmaceuticals, Inc. | 10 | $178 |
| Gilead Sciences, Inc. | 10 | $165 |
| PFIZER INC. | 6 | $117 |
Products named: TREMFYA, XIFAXAN, DUPIXENT, REZDIFFRA, CREON, ENTYVIO, IQIRVO, SKYRIZI.
Industry payments across MD — which companies pay providers there.
